Clinical trial Recruiting at 1 site Observational Ages 18 and up

Identifying patients at risk of heart attack during elective PCI

Official title: Ability of a Precision Medicine Approach to Identify Stable CAD Patients Undergoing Elective PCI Who Are at Risk of Peri-PCI Myocardial Infarction/Myocardial Injury: The ABCD-Gene Prospective Study

Run by University of Florida · NCT05332262 · Data updated 2026-11-12

This study is testing a new scoring system to see if it can help identify patients with stable heart disease who are at risk of having a heart attack during a specific heart procedure called PCI.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment500 (estimated)
SponsorUniversity of Florida
Academic / other
Locations1 site (Jacksonville, Florida)
StatusRecruiting
StartedMay 23, 2022
Main results expectedDecember 2026
Study endsAugust 2027
Registry record updatedJanuary 20, 2026
Trial IDNCT05332262 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adults aged 18 and older with stable coronary artery disease undergoing elective PCI who are negative for troponin before the procedure.

Probably not a fit

Patients currently experiencing a myocardial infarction or those on alternative antiplatelet therapies like prasugrel or ticagrelor will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to validate the ABCD-GENE score, a precision medicine tool that integrates genetic and clinical data, to identify patients with stable coronary artery disease (CAD) who are at risk of experiencing myocardial infarction or myocardial injury during elective percutaneous coronary intervention (PCI). The study will involve a prospective cohort of 500 patients undergoing elective PCI while being treated with clopidogrel. By assessing platelet reactivity and troponin levels, the researchers hope to stratify patients based on their risk and potentially improve treatment outcomes. The findings could lead to better management strategies for patients undergoing PCI.

Why it matters

Potential benefit: If successful, this study could help identify patients at high risk for complications during PCI, allowing for tailored antiplatelet therapy and improved patient outcomes.

How similar studies have gone: Other studies have shown promise in using genetic and clinical factors to predict thrombotic complications in PCI, but this specific approach with the ABCD-GENE score is novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion criteria:

1. Stable CAD undergoing elective PCI;
2. Male or females, Age ≥ 18 years old;
3. Troponin negative before PCI\*;
4. Background of aspirin therapy;

   * If troponin is unknown before coronary angiography and no clinical signs of acute coronary syndrome is present, a troponin will not be collected as this is line with standard practice.

Exclusion criteria:

1. Current presentation with myocardial infarction;
2. On treatment with prasugrel or ticagrelor;
3. Documented hypersensitivity to clopidogrel;
4. Use of an intravenous antiplatelet therapy (i.e., cangrelor or GPI) during PCI;
5. Unable to provide written informed consent.

Where it's running

  • University of Florida Jacksonville
    Jacksonville, Florida, United States
    Recruiting

Study contacts

  • Principal investigator: Francesco Franchi, MD — University of Florida College of Medicine Jacksonville
  • Study coordinator: Francesco Franchi, MD
  • Email: francesco.franchi@jax.ufl.edu
  • Phone: 9042442060

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.